Concerning the central role of EGFR and PD-L1 in the pathogenesis and therapy of HNSCC, hypoxia-mediated modulation of receptor tyrosine kinase signaling or the immunologic status might represent another paradigm for therapy resistance mediated by tumor microenvironmental traits. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.